IMKELDI vs KOSELUGO

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 20, 2026·How we rate

Possible drug interaction. IMKELDI and KOSELUGO are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	IMKELDI	KOSELUGO
Rating	New	70/100
Pharmacy pays	~$25.80 /30	—
Type	RX	RX
Active ingredient	IMATINIB MESYLATE	SELUMETINIB SULFATE
Manufacturer	Shorla Oncology	Astrazeneca
Dosage forms	Solution	Capsule, Powder
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	None
Treats	Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome	Neurofibromatosis 1

imkeldi koselugo

Rating

New

70/100

Pharmacy pays

~$25.80 /30

—

Type

Active ingredient

IMATINIB MESYLATE

SELUMETINIB SULFATE

Manufacturer

Shorla Oncology

Astrazeneca

Dosage forms

Solution

Capsule, Powder

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

Neurofibromatosis 1

Frequently asked questions

What is the difference between Imkeldi and Koselugo?

Imkeldi contains Imatinib Mesylate, while Koselugo contains Selumetinib Sulfate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.